Close Menu

NEW YORK -- British bloodtesting company Biosignatures announced last week it has raised £3.5 million ($4.2 million) in funding.  

The financing round was led by Accelerated Digital Ventures from its British Business Bank ECF fund.  

Biosignatures intends to use the money to analyze biobank samples to develop 20 new diagnostic screening tests targeted at cancer and dementia. All 20 tests would be run on one blood sample, the Newcastle Upon Tyne-based company said.  

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.